[Back to Overwiew]  [IACM Homepage]


IACM-Bulletin of 01 January 2012

France: Two acquittals by criminal courts due to medical use of cannabis

According to the television channel France 2 on the evening of 28 December two different French criminal courts have acquitted two patients suffering from chronic diseases from the charge of illegal cannabis possession in the past days. One of them is an AIDS patient who was arrested due to the possession of 400 grams cannabis and declared before the court that it was for personal use and for medicinal purposes. The second acquittal happened in the case of a multiple sclerosis sufferer.

According to the television report the prosecutor said in the trial against the AIDS patient: "The law has to protect the individuals and in this case it does not protect him, but puts him in jeopardy if it denies him access to his medication." In the other case the judge said that certain "intolerable painful conditions can only be alleviated by the use of cannabis." These are the first published cases of acquitalls due to the medical use of cannabis in France.

More at:
- www.pluzz.fr/jt-20h-2011-12-28-20h00.html
- https://www.cannaway.net/actualite/les-tribunaux-francais-depenalisent-le-cannabis-medical-2/

(Sources: France 2 of 28 December 2011, Cannaway of 28 December 2011)

News in brief

Sweden: Sativex granted regulatory approval
The cannabis extract Sativex received regulatory approval in Sweden for the treatment of spasticity due to multiple sclerosis. Sativex contains equal amounts of THC and CBD and is sprayed into the mouth. In EURope it is currently available in the UK, Germany, Spain and Denmark. (Source: GW Pharmaceuticals of 22 December 2011)

USA: Colorado seeks new classification of cannabis
Colorado has become the third state to ask the federal government to reclassify cannabis in a way that allows doctors to prescribe it as a medical treatment. The head of Colorado's Department of Revenue made the request in a letter sent 22 December. The letter says the discrepancy between state law and federal drug law, which does not permit medicinal uses of cannabis, is problematic. In November 2011, the governors of Washington and Rhode Island also asked that the government to list cannabis (marijuana) in the same category as morphine and oxycodone. (Source: Associated Press of 28 December 2011)

Holland: NCSM
The website of the Dutch NCSM (‘Dutch Association for Legal Cannabis and its Constituents as Medicine’) is now available in English. (Source: Personal communication, www.ncsm.nl)

Science: Safety of cannabidiol (CBD)
According to a review of studies on cannabidiol (CBD) this non-psychotropic cannabinoid of the cannabis plant "may be safe in humans and animals." "Several studies suggest that CBD is non-toxic in non-transformed cells and does not induce changes on food intake, does not induce catalepsy, does not affect physiological parameters (heart rate, blood pressure and body temperature), does not affect gastrointestinal transit and does not alter psychomotor or psychological functions." (Source: Bergamaschi MM, et al. Curr Drug Saf 2011;6(4):237-49.)

Science: CBD inhibits lung cancer metastasis
According to cell experiments at the University of Rostock, Germany, cannabidiol (CBD) inhibits lung cancer metastasis by increasing the concentration of a certain protein (ICAM-1). (Source: Ramer R, et al. FASEB J. 2011 Dec 23. [in press])

Science: Number of CB1 receptors during adolescence
According to research at the Schizophrenia Research Institute in Sydney, Australia, the number of CB1 receptors in the brain is higher in adult compaired to adolescent rats. Researchers noted that this increase "during the transition from adolescence to adulthood, is the opposite of most other neuroreceptor systems undergoing pruning during this period." (Source: Verdurand M, et al. Int J Mol Imaging. 2011;2011:548123.)

Science: Reversal of liver cirrhosis by CB1 receptor antagonist
According to animal research of Italian scientists the CB1 receptor antagonist rimonabant reversed chemically induced liver fibrosis in rats. Fibrosis was significantly reduced in rats treated with rimonabant. The number of CB1 and CB2 receptors was increased in cirrhotic animals. Pharmacological CB1 receptor antagonism was associated with a further increase of the CB2 receptor. (Source: Giannone FA, et al. Lab Invest. 2011 Dec 19. [in press])

Science: Cannabinoid receptors increased in brain tumours
According to research by Chinese scientists the endocannabinoid system is altered in human gliomas, certain brain tumours. The concentration of the endocannabinoid anandamide was increased while the level of 2-AG (2-arachidonylglycerol) was increased in glioma tissue. The levels of cannabinoid receptors, CB1 and CB2, were also elevated. (Source: Wu X, et al. J Neurochem. 2011 Dec 16. [in press])

Science: Effect of rimonabant on metabolism
According to a clinical study with 76 obese subjects who received rimonabant (20 mg/day) or placebo for 12 months "improvements observed in insulin regulation of free fatty acid and glucose metabolism with rimonabant treatment in humans was not greater than that predicted by weight loss alone." (Source: Triay J, et al. J Clin Endocrinol Metab. 2011 Dec 14. [in press])

A glimpse @ the past

One year ago

Two years ago

[Back to Overwiew]  [IACM Homepage]


up

Webinars 2020

In October 2020 the IACM is organising a webinar series. Among the speakers are Roger Pertwee, Raphael Mechulam, Manuel Guzman, Ethan Russo and Kirsten Müller-Vahl. There will be subtitles for several languages after the webinars. Access is free for regular memebers of the IACM. Please find here the brochure for sponsors. Plaese find here Information on registration fees and a link for registration.

IACM Conference 2020

The IACM will hold its 11th Conference on Cannabinoids in Medicine in collaboration with the Asociación Mexicana de Medicina Cannabinodie from 5 to 7 November 2020 in Mexico City. It will be a virtual congress. Plaese find here Information on registration fees and a link for registration.

IACM Conference 2021

The 12th IACM Conference on Cannabinoids in Medicine will be held in Basel, Switzerland, from 14 to 16 October 2021.

Members only

Regular members can sign up for the new member area of the IACM to access exclusive content.

You need to become a regular member of the IACM to access the new member area.

IACM on Twitter

Follow us on twitter @IACM_Bulletin where you can send us inquiries and receive updates on research studies and news articles.